3-甲基-1H-吡咯-4-甲醛 | 112758-40-4

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-甲基-1H-吡咯-4-甲醛
• 中文别名: 3-甲基吡唑-4-甲醛；3-甲基-1H-吡唑-4-甲醛
• 英文名称: 3-methyl-1H-pyrazole-4-carbaldehyde
• 英文别名: 5-methyl-1H-pyrazole-4-carbaldehyde
• CAS: 112758-40-4
• 化学式: C₅H₆N₂O
• mdl: MFCD01313822
• 分子量: 110.115
• InChiKey: NWDMGTFNIOCVDU-UHFFFAOYSA-N

物化性质

• 熔点：
  107-108.5°C
• 沸点：
  295.9±20.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090
• 危险品标志：
  Xi
• 危险类别码：
  R22,R36/37/38
• WGK Germany：
  3
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件为0-10°C，应置于惰性气体中，并避免与空气、水分接触以及受热引起的分解。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Methyl-1h-pyrazole-4-carbaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Methyl-1h-pyrazole-4-carbaldehyde
CAS number: 112758-40-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H6N2O
Molecular weight: 110.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-甲基-1H-吡咯-4-甲醛是一种醛类衍生物，可用作有机合成中间体。

制备

在装有温度计和回流管的250毫升三口烧瓶中加入丙酮缩氨脲和无水乙醇，在搅拌状态下滴加N,N-二甲基甲酰胺，并使用浓盐酸调节pH至2.5。随后加热使反应液回流，持续12小时后，向反应液中加入30%的氢氧化钠溶液以调节pH值至约13，冷却后抽滤，用正丙醇进行重结晶得到产品，最后干燥并称重即得3-甲基-1H-吡咯-4-甲醛。

反应信息

• 作为反应物：
  描述：

  3-甲基-1H-吡咯-4-甲醛 在 trans-N,N'-dimethyl-1,2-cyclohexyldiamine 、 copper(l) iodide 甲醇 、 sodium tetrahydroborate 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 34.5h， 生成 (2-(4-((2'-氯-4',4'-二氟-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-C]吡喃]-1-基)甲基)-3-甲基-1H-吡唑-1-基)吡啶-3-基)甲醇
  参考文献：
  名称：

  SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS

  摘要：

  一个公式为ORL-1受体拮抗剂： 其用途和制备方法已被描述。

  公开号：

  US20110118251A1
• 作为产物：
  描述：

  3-甲基-3-吡唑啉-5-酮 、 N,N-二甲基甲酰胺 在 三氯氧磷 作用下， 反应 6.0h， 以83%的产率得到3-甲基-1H-吡咯-4-甲醛
  参考文献：
  名称：

  Sen, Sandip; Bhaumik, Pradip; Roy, Biswabara, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2016, vol. 55B, # 4, p. 507 - 516

  摘要：

  DOI：

文献信息

• COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES
  申请人：Yuhan Corporation

  公开号：US20160102076A1

  公开（公告）日：2016-04-14

  The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.

  本发明提供了一类新的蛋白激酶抑制剂，氨基嘧啶衍生物及其药用可接受的盐，用于治疗细胞增殖性疾病和紊乱，如癌症和免疫疾病。本发明提供了合成和给药蛋白激酶抑制剂化合物的方法。本发明还提供了包含至少一种蛋白激酶抑制剂化合物的药物配方，以及药用可接受的载体、稀释剂或辅料。该发明还提供了在合成氨基嘧啶衍生物过程中产生的有用中间体。
• [EN] PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PYRAZOLOSPIROCÉTONE ACÉTL-COA CARBOXYLASE
  申请人：PFIZER

  公开号：WO2009144554A1

  公开（公告）日：2009-12-03

  The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供了式(1)的化合物或所述化合物的药用可接受盐，其中R1、R2和R3如本文所述；其药物组合物；以及用于治疗通过抑制动物中的乙酰辅酶A羧化酶酶活性来调节的疾病、病症或障碍的使用方法。
• Pyrazolopyrimidines as therapeutic agents
  申请人：Abbott Laboratories

  公开号：US20020156081A1

  公开（公告）日：2002-10-24

  The present invention provides compounds of Formula I, 1 including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R 2 , and R 3 are defined as described herein.

  本发明提供了公式I的化合物，包括其药学上可接受的盐和/或前药，其中G、R2和R3的定义如本文所述。
• QUINAZOLINONES AS PARP14 INHIBITORS
  申请人：Ribon Therapeutics Inc.

  公开号：US20190194174A1

  公开（公告）日：2019-06-27

  The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.

  本发明涉及喹唑啉酮和相关化合物，它们是PARP14的抑制剂，例如在癌症和炎症性疾病的治疗中是有用的。
• [EN] SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS DE SPIROPIPÉRIDINE EN TANT QU'ANTAGONISTES DE RÉCEPTEUR ORL-1
  申请人：LILLY CO ELI

  公开号：WO2011060217A1

  公开（公告）日：2011-05-19

  An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.

  一种ORL-1受体拮抗剂的公式：描述了其用途以及其制备方法。ORL-1拮抗剂被认为在治疗抑郁症和/或治疗超重、肥胖和/或超重或肥胖后的体重维持治疗中是有用的。某些化合物还通过动物模型证明，本发明的化合物对治疗偏头痛是有用的。